Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins

Vaccine

Volumn 25, Issue 8, 2007, Pages 1452-1463

  Haller, Aurelia A ^a   Lauer, Georg M ^b   King, Thomas H ^a   Kemmler, Charles ^a   Fiolkoski, Valerie ^a   Lu, Yingnian ^a   Bellgrau, Don ^a,c   Rodell, Timothy C ^a   Apelian, David ^a   Franzusoff, Alex ^a   Duke, Richard C ^a,c  

^a GlobeImmune Inc   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

HCV; Hepatitis C; Immunotherapy; S. cerevisiae; Vaccine; Yeast

Indexed keywords

CORE PROTEIN; CYTOKINE; GAMMA INTERFERON; GI 4014; GI 5003; GI 5005; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 3 VIRUS CORE PROTEIN CONJUGATE; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN;

ACTIVE IMMUNIZATION; ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG POTENCY; FEMALE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE; TH1 CELL; TUMOR CELL; YEAST CELL;

ANIMALS; CELL LINE, TUMOR; CYTOKINES; HELA CELLS; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECOMBINANT FUSION PROTEINS; SACCHAROMYCES CEREVISIAE; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; VIRAL CORE PROTEINS; VIRAL HEPATITIS VACCINES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 33846088350     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.10.035     Document Type: Article

References (30)

1. Shepard C.W., Finelli L., and Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5 9 (2005) 558-567
2. Lauer G.M., and Walker B.D. Hepatitis C virus infection. N Engl J Med 345 1 (2001) 41-52
3. Dienstag J.L., and McHutchison J.G. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 130 1 (2006) 231-264
4. Rehermann B., and Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5 3 (2005) 215-229
5. Shoukry N.H., Cawthon A.G., and Walker C.M. Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu Rev Microbiol 58 (2004) 391-424
6. Mascola J.R., Sambor A., Beaudry K., Santra S., Welcher B., Louder M.K., et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol 79 2 (2005) 771-779
7. Xin K.Q., Jounai N., Someya K., Honma K., Mizuguchi H., Naganawa S., et al. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther 12 24 (2005) 1769-1777
8. Nimal S., Heath A.W., and Thomas M.S. Enhancement of immune responses to an HIV gp120 DNA vaccine by fusion to TNF alpha cDNA. Vaccine 24 16 (2006) 3298-3308
9. Akira S., Takeda K., and Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2 8 (2001) 675-680
10. Gantner B.N., Simmons R.M., Canavera S.J., Akira S., and Underhill D.M. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med 197 9 (2003) 1107-1117
11. Medzhitov R., and Janeway C.A. Decoding the patterns of self and nonself by the innate immune system. Science 296 5566 (2002) 298-300
12. Ozinsky A., Underhill D.M., Fontenot J.D., Hajjar A.M., Smith K.D., Wilson C.B., et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA 97 25 (2000) 13766-13771
13. Underhill D.M. Toll-like receptors: networking for success. Eur J Immunol 33 7 (2003) 1767-1775
14. Underhill D.M., and Gantner B. Integration of Toll-like receptor and phagocytic signaling for tailored immunity. Microbes Infect 6 15 (2003) 1368-1373
15. Huang Q., Liu D., Majewski P., Schulte L.C., Korn J.M., Young R.A., et al. The plasticity of dendritic cell responses to pathogens and their components. Science 294 5543 (2001) 870-875
16. Ikeda Y., Adachi Y., Ishibashi K., Miura N., and Ohno N. Activation of toll-like receptor-mediated NF-kappa beta by zymosan-derived water-soluble fraction: possible contribution of endotoxin-like substances. Immunopharmacol Immunotoxicol 27 2 (2005) 285-298
17. Tada H., Nemoto E., Shimauchi H., Watanabe T., Mikami T., Matsumoto T., et al. Saccharomyces cerevisiae- and Candida albicans-derived mannan induced production of tumor necrosis factor alpha by human monocytes in a CD14- and Toll-like receptor 4-dependent manner. Microbiol Immunol 46 7 (2002) 503-512
18. Stubbs A.C., Martin K.S., Coeshott C., Skaates S.V., Kuritzkes D.R., Bellgrau D., et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 7 5 (2001) 625-629
19. Lu Y., Bellgrau D., Dwyer-Nield L.D., Malkinson A.M., Duke R.C., Rodell T.C., et al. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res 64 15 (2004) 5084-5088
20. Franzsusoff A., Duke R.C., King T.H., Lu Y., and Rodell T.C. Yeasts encoding tumor antigens in cancer immunotherapy. Expert Opin Biol Ther 5 4 (2005) 565-575
21. Bukh J., Purcell R.H., and Miller R.H. Importance of primer selection for the detection of hepatitis C virus RNA with the polymerase chain reaction assay. Proc Natl Acad Sci USA 89 1 (1992) 187-191
22. Choo Q., Kuo G., Ralston R., Weiner A., Chien D., Nest G.V., et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 91 4 (1994) 1294-1298
23. Nevens F., Roskams T., Van Vlierberghe H., Horsmans Y., Sprengers D., Elewaut A., et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 38 5 (2003) 1289-1296
24. Bartenschlager R., and Lohmann V. Replication of hepatitis C virus. J Gen Virol 81 7 (2000) 1631-1648
25. Penin F., Dubuisson J., Rey F.A., Moradpour D., and Pawlotsky J.M. Structural biology of hepatitis C virus. Hepatology 39 1 (2004) 5-19
26. Pichuantes S., Nguyen A.T., and Franzusoff A. Expression of heterologous gene products in yeast. In: Cleland J.L., and Craik C.S. (Eds). Protein engineering-principles and practice (1996), Wiley-Liss, New York 129-162
27. Schreuder M.P., Mooren A.T., Toschka H.Y., Verrips C.T., and Klis F.M. Immobilizing proteins on the surface of yeast cells. Trends Biotechnol 14 4 (1996) 115-120
28. Schreuder M.P., Deen C., Boersma W.J., Pouwels P.H., and Klis F.M. Yeast expressing hepatitis B virus surface antigen determinants on its surface: implications for a possible oral vaccine. Vaccine 14 5 (1996) 383-388
29. Shin S.J., Shin S.W., Choi E.J., Lee D.Y., Ahn J.M., Yang M.S., et al. A predictive model for the level of sIgA based on IgG levels following the oral administration of antigens expressed in Saccharomyces cerevisiae. J Vet Sci 6 4 (2005) 305-309
30. Shin S.J., Bae J.L., Cho Y.W., Lee D.Y., Kim D.H., Yang M.S., et al. Induction of antigen-specific immune responses by oral vaccination with Saccharomyces cerevisiae expressing Actinobacillus pleuropneumoniae ApxIIA. FEMS Immunol Med Microbiol 43 2 (2005) 155-164